Our Team
Alan Tomusiak, PhD
CEO
After earning his degree from Stanford University, Alan developed a deep passion for addressing aging and cancer prevention. He studied age-associated diseases through a PhD at the Buck Institute before founding Permanence Bio to translate these insights into therapies.
Carlos Galicia, PhD
Director of Research
Carlos has long been interested in how aging limits human potential. As an undergraduate at Idaho, he studied CNS regeneration, then earned a PhD in the Biology of Aging at the Buck Institute. Now, as Director of Research at Permanence Bio, he builds systems to discover cancer-preventing compounds.
Eddie Anderton, PhD
Head of Development
Eddie was drawn to longevity, believing aging is our era's most pressing medical problem. He studied Biochemistry at Oxford, then earned a PhD in Aging Biology at the Buck Institute. Now, Head of Development at Permanence Bio, he is spearheading the advancement of lead compounds through IND-enabling studies into the clinic.
Katrina Mae Reyes
Computational Scientist
During her time at UCLA, Katrina researched cancer immunology—how cytokines impact the tumor microenvironment in colorectal cancer. She earned a master's in molecular science and software engineering from UC Berkeley. Now, at Permanence Bio, she builds and validates the AI platform that creates Permanence Bio's compounds.
Jim Frederich, PhD
Chemistry Advisor
An expert in the intersection of organic chemistry and cancer, Dr. Jim Frederich and his laboratory at Florida State University are working with Permanence Bio to develop the next generation of therapeutics for preventing damage to the genome.
READ BIO
Advisors
Jim Frederich, PhD
Chemistry Advisor
An expert in the intersection of organic chemistry and cancer, Dr. Jim Frederich and his laboratory at Florida State University are working with Permanence Bio to develop the next generation of therapeutics for preventing damage to the genome.
READ BIO
Eduardo Vilar-Sanchez, MD, PhD
Clinical Advisor
Dr. Vilar-Sanchez is a physician-scientist at MD Anderson Cancer Center specializing in hereditary cancer syndromes and cancer prevention. His work on Lynch syndrome and DNA repair mechanisms helps shape the company’s clinical strategy.
READ BIO
Sir John Burn, MD
Clinical Advisor
A global leader in cancer prevention, Sir John Burn has over two decades of experience conducting trials in Lynch Syndrome. His expertise in translational medicine is instrumental in guiding the company’s approach to early intervention.
READ BIO
Vera Gorbunova, PhD
Scientific Advisor
Dr. Gorbunova is a leader in aging and cancer resistance research. Her work on DNA repair in long-lived species provides valuable insights into new approaches for reducing cancer risk at the cellular level.
READ BIO
Winfried Edelmann, PhD
Scientific Advisor
Dr. Edelmann is an expert in DNA mismatch repair and its role in cancer susceptibility. His foundational research has been critical in understanding how genomic instability drives cancer, helping inform the company’s therapeutic development.
READ BIO
Jason Sheltzer, PhD
Scientific Advisor
Dr. Sheltzer’s research focuses on cancer genetics and identifying new therapeutic targets. His expertise in oncogene function and tumor vulnerabilities contributes to the scientific foundation of the company’s prevention strategies.
READ BIO
Alex Cagan, PhD
Scientific Advisor
Dr. Cagan’s work at the Sanger Institute explores how mutations accumulate in healthy tissues over time. His research helps shape strategies to slow or prevent the cellular changes that lead to cancer.
READ BIO
Matt Donne, PhD
Operational Advisor
Matt Donne brings deep experience in biotech operations, strategy, and planning. He has been deeply impactful in steering Permanence Bio through its early stages.
READ BIO
Eugene Kim, JD
Legal Advisor
Eugene Kim specializes in biotech law, guiding early-stage companies on corporate structuring, IP strategy, and regulatory compliance.
READ BIO